CytoMed Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
CytoMed Therapeutics has a total shareholder equity of SGD10.2M and total debt of SGD425.7K, which brings its debt-to-equity ratio to 4.2%. Its total assets and total liabilities are SGD10.9M and SGD748.8K respectively.
Key information
4.2%
Debt to equity ratio
S$425.72k
Debt
| Interest coverage ratio | n/a |
| Cash | S$6.82m |
| Equity | S$10.16m |
| Total liabilities | S$748.82k |
| Total assets | S$10.91m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GDTC's short term assets (SGD7.7M) exceed its short term liabilities (SGD357.9K).
Long Term Liabilities: GDTC's short term assets (SGD7.7M) exceed its long term liabilities (SGD390.9K).
Debt to Equity History and Analysis
Debt Level: GDTC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GDTC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GDTC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GDTC has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24.4% each year.